Koichi Takahashi
Overview
Explore the profile of Koichi Takahashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
381
Citations
7205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series
Marvin-Peek J, Sasaki K, Kontoyiannis D, Adachi J, Ohanian M, Takahashi K, et al.
Front Med (Lausanne)
. 2024 Aug;
11:1402897.
PMID: 39149601
Patients with leukemia experience profound immunosuppression both from their underlying disease as well as chemotherapeutic treatment. Little is known about the prevalence and clinical presentation of nontuberculous mycobacteria (NTM) in...
13.
Urrutia S, Takahashi K
Int J Hematol
. 2024 Jul;
120(4):439-454.
PMID: 39085680
The development of molecularly targeted therapy for acute myeloid leukemia is progressing at an accelerated pace. Therapies targeting FLT3, IDH1, IDH2, and BCL2 have been approved in the last 5 ...
14.
Zhang L, Hsu J, Braekeleer E, Chen C, Patel T, Martell A, et al.
Elife
. 2024 Jun;
12.
PMID: 38896450
The DNA damage response is critical for maintaining genome integrity and is commonly disrupted in the development of cancer. PPM1D (protein phosphatase Mg/Mn-dependent 1D) is a master negative regulator of...
15.
Gener-Ricos G, Bewersdorf J, Loghavi S, Bataller A, Goldberg A, Sasaki K, et al.
Leuk Lymphoma
. 2024 Jun;
65(10):1511-1515.
PMID: 38856690
No abstract available.
16.
Uryu H, Saeki K, Haeno H, Kapadia C, Furudate K, Nangalia J, et al.
bioRxiv
. 2024 Jun;
PMID: 38826462
Normal hematopoietic stem and progenitor cells (HSPCs) inherently accumulate somatic mutations and lose clonal diversity with age, processes implicated in the development of myeloid malignancies . The impact of exogenous...
17.
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla J, Ma F, Ganan-Gomez I, Yang H, et al.
Cell Rep Med
. 2024 May;
5(6):101585.
PMID: 38781960
RAS pathway mutations, which are present in 30% of patients with chronic myelomonocytic leukemia (CMML) at diagnosis, confer a high risk of resistance to and progression after hypomethylating agent (HMA)...
18.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo C, et al.
Haematologica
. 2024 May;
109(11):3543-3556.
PMID: 38695144
Patients with relapsed acute myeloid leukemia (AML) experience dismal outcomes. We performed a comprehensive analysis of patients with relapsed AML to determine the genetic dynamics and factors predicting survival. We...
19.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, et al.
Am J Hematol
. 2024 Apr;
99(7):1434-1436.
PMID: 38613831
No abstract available.
20.
Bataller A, Gener-Ricos G, Almanza-Huante E, Chien K, Urrutia S, Bazinet A, et al.
Blood Adv
. 2024 Mar;
8(11):2695-2706.
PMID: 38513082
Therapy-related myeloid neoplasms (t-MNs) arise after exposure to cytotoxic therapies and are associated with high-risk genetic features and poor outcomes. We analyzed a cohort of patients with therapy-related chronic myelomonocytic...